SrasV1, PubMed, Corpus, bibRecord, 001C24

The SARS-CoV ferret model in an infection-challenge study.

Identifieur interne : 001C24 ( PubMed/Corpus ); précédent : 001C23; suivant : 001C25

The SARS-CoV ferret model in an infection-challenge study.

Auteurs : Yong-Kyu Chu ; Georgia D. Ali ; Fuli Jia ; Qianjun Li ; David Kelvin ; Ronald C. Couch ; Kevin S. Harrod ; Julie A. Hutt ; Cheryl Cameron ; Susan R. Weiss ; Colleen B. Jonsson

Source :

Virology [ 0042-6822 ] ; 2008.

RBID : pubmed:18234270

English descriptors

KwdEn :
- Animals, Antibodies, Viral (blood), Body Temperature, Disease Models, Animal, Ferrets, Leukocyte Count, Lung (pathology), Lung (virology), Lymphocyte Count, Male, Nasal Cavity (virology), Neutralization Tests, Pharynx (virology), SARS Virus (physiology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (pathology), Severe Acute Respiratory Syndrome (physiopathology), Severe Acute Respiratory Syndrome (virology).
MESH :
- chemical , blood : Antibodies, Viral.
- immunology : Severe Acute Respiratory Syndrome.
- pathology : Lung, Severe Acute Respiratory Syndrome.
- physiology : SARS Virus.
- physiopathology : Severe Acute Respiratory Syndrome.
- virology : Lung, Nasal Cavity, Pharynx, Severe Acute Respiratory Syndrome.
- Animals, Body Temperature, Disease Models, Animal, Ferrets, Leukocyte Count, Lymphocyte Count, Male, Neutralization Tests.

Abstract

Phase I human clinical studies involving therapeutics for emerging and biodefense pathogens with low incidence, such as the severe acute respiratory syndrome coronavirus (SARS-CoV), requires at a minimum preclinical evaluation of efficacy in two well-characterized and robust animal models. Thus, a ferret SARS-CoV model was evaluated over a period of 58 days following extensive optimization and characterization of the model in order to validate clinical, histopathological, virological and immunological endpoints. Ferrets that were infected intranasally with 10(3) TCID50 SARS-CoV showed higher body temperature (2-6 d.p.i.), sneezing (5-10 d.p.i.), lesions (5-7 d.p.i.) and decreased WBC/lymphocytes (2-5 d.p.i.). SARS-CoV was detected up to 7 d.p.i. in various tissues and excreta, while neutralizing antibody titers rose at 7 d.p.i. and peaked at 14 d.p.i. At 29 d.p.i., one group was challenged with 10(3) TCID50 SARS-CoV, and an anamnestic response in neutralizing antibodies was evident with no detectable virus. This study supports the validity of the ferret model for use in evaluating efficacy of potential therapeutics to treat SARS.

DOI: 10.1016/j.virol.2007.12.032
PubMed: 18234270

Links to Exploration step

pubmed:18234270

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The SARS-CoV ferret model in an infection-challenge study.</title>
<author><name sortKey="Chu, Yong Kyu" sort="Chu, Yong Kyu" uniqKey="Chu Y" first="Yong-Kyu" last="Chu">Yong-Kyu Chu</name>
<affiliation><nlm:affiliation>Department of Biochemistry and Molecular Biology, Southern Research Institute, Birmingham, AL, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ali, Georgia D" sort="Ali, Georgia D" uniqKey="Ali G" first="Georgia D" last="Ali">Georgia D. Ali</name>
</author>
<author><name sortKey="Jia, Fuli" sort="Jia, Fuli" uniqKey="Jia F" first="Fuli" last="Jia">Fuli Jia</name>
</author>
<author><name sortKey="Li, Qianjun" sort="Li, Qianjun" uniqKey="Li Q" first="Qianjun" last="Li">Qianjun Li</name>
</author>
<author><name sortKey="Kelvin, David" sort="Kelvin, David" uniqKey="Kelvin D" first="David" last="Kelvin">David Kelvin</name>
</author>
<author><name sortKey="Couch, Ronald C" sort="Couch, Ronald C" uniqKey="Couch R" first="Ronald C" last="Couch">Ronald C. Couch</name>
</author>
<author><name sortKey="Harrod, Kevin S" sort="Harrod, Kevin S" uniqKey="Harrod K" first="Kevin S" last="Harrod">Kevin S. Harrod</name>
</author>
<author><name sortKey="Hutt, Julie A" sort="Hutt, Julie A" uniqKey="Hutt J" first="Julie A" last="Hutt">Julie A. Hutt</name>
</author>
<author><name sortKey="Cameron, Cheryl" sort="Cameron, Cheryl" uniqKey="Cameron C" first="Cheryl" last="Cameron">Cheryl Cameron</name>
</author>
<author><name sortKey="Weiss, Susan R" sort="Weiss, Susan R" uniqKey="Weiss S" first="Susan R" last="Weiss">Susan R. Weiss</name>
</author>
<author><name sortKey="Jonsson, Colleen B" sort="Jonsson, Colleen B" uniqKey="Jonsson C" first="Colleen B" last="Jonsson">Colleen B. Jonsson</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2008">2008</date>
<idno type="RBID">pubmed:18234270</idno>
<idno type="pmid">18234270</idno>
<idno type="doi">10.1016/j.virol.2007.12.032</idno>
<idno type="wicri:Area/PubMed/Corpus">001C24</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001C24</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The SARS-CoV ferret model in an infection-challenge study.</title>
<author><name sortKey="Chu, Yong Kyu" sort="Chu, Yong Kyu" uniqKey="Chu Y" first="Yong-Kyu" last="Chu">Yong-Kyu Chu</name>
<affiliation><nlm:affiliation>Department of Biochemistry and Molecular Biology, Southern Research Institute, Birmingham, AL, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ali, Georgia D" sort="Ali, Georgia D" uniqKey="Ali G" first="Georgia D" last="Ali">Georgia D. Ali</name>
</author>
<author><name sortKey="Jia, Fuli" sort="Jia, Fuli" uniqKey="Jia F" first="Fuli" last="Jia">Fuli Jia</name>
</author>
<author><name sortKey="Li, Qianjun" sort="Li, Qianjun" uniqKey="Li Q" first="Qianjun" last="Li">Qianjun Li</name>
</author>
<author><name sortKey="Kelvin, David" sort="Kelvin, David" uniqKey="Kelvin D" first="David" last="Kelvin">David Kelvin</name>
</author>
<author><name sortKey="Couch, Ronald C" sort="Couch, Ronald C" uniqKey="Couch R" first="Ronald C" last="Couch">Ronald C. Couch</name>
</author>
<author><name sortKey="Harrod, Kevin S" sort="Harrod, Kevin S" uniqKey="Harrod K" first="Kevin S" last="Harrod">Kevin S. Harrod</name>
</author>
<author><name sortKey="Hutt, Julie A" sort="Hutt, Julie A" uniqKey="Hutt J" first="Julie A" last="Hutt">Julie A. Hutt</name>
</author>
<author><name sortKey="Cameron, Cheryl" sort="Cameron, Cheryl" uniqKey="Cameron C" first="Cheryl" last="Cameron">Cheryl Cameron</name>
</author>
<author><name sortKey="Weiss, Susan R" sort="Weiss, Susan R" uniqKey="Weiss S" first="Susan R" last="Weiss">Susan R. Weiss</name>
</author>
<author><name sortKey="Jonsson, Colleen B" sort="Jonsson, Colleen B" uniqKey="Jonsson C" first="Colleen B" last="Jonsson">Colleen B. Jonsson</name>
</author>
</analytic>
<series><title level="j">Virology</title>
<idno type="ISSN">0042-6822</idno>
<imprint><date when="2008" type="published">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibodies, Viral (blood)</term>
<term>Body Temperature</term>
<term>Disease Models, Animal</term>
<term>Ferrets</term>
<term>Leukocyte Count</term>
<term>Lung (pathology)</term>
<term>Lung (virology)</term>
<term>Lymphocyte Count</term>
<term>Male</term>
<term>Nasal Cavity (virology)</term>
<term>Neutralization Tests</term>
<term>Pharynx (virology)</term>
<term>SARS Virus (physiology)</term>
<term>Severe Acute Respiratory Syndrome (immunology)</term>
<term>Severe Acute Respiratory Syndrome (pathology)</term>
<term>Severe Acute Respiratory Syndrome (physiopathology)</term>
<term>Severe Acute Respiratory Syndrome (virology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lung</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Lung</term>
<term>Nasal Cavity</term>
<term>Pharynx</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Body Temperature</term>
<term>Disease Models, Animal</term>
<term>Ferrets</term>
<term>Leukocyte Count</term>
<term>Lymphocyte Count</term>
<term>Male</term>
<term>Neutralization Tests</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Phase I human clinical studies involving therapeutics for emerging and biodefense pathogens with low incidence, such as the severe acute respiratory syndrome coronavirus (SARS-CoV), requires at a minimum preclinical evaluation of efficacy in two well-characterized and robust animal models. Thus, a ferret SARS-CoV model was evaluated over a period of 58 days following extensive optimization and characterization of the model in order to validate clinical, histopathological, virological and immunological endpoints. Ferrets that were infected intranasally with 10(3) TCID50 SARS-CoV showed higher body temperature (2-6 d.p.i.), sneezing (5-10 d.p.i.), lesions (5-7 d.p.i.) and decreased WBC/lymphocytes (2-5 d.p.i.). SARS-CoV was detected up to 7 d.p.i. in various tissues and excreta, while neutralizing antibody titers rose at 7 d.p.i. and peaked at 14 d.p.i. At 29 d.p.i., one group was challenged with 10(3) TCID50 SARS-CoV, and an anamnestic response in neutralizing antibodies was evident with no detectable virus. This study supports the validity of the ferret model for use in evaluating efficacy of potential therapeutics to treat SARS.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18234270</PMID>
<DateCompleted><Year>2008</Year>
<Month>05</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>01</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0042-6822</ISSN>
<JournalIssue CitedMedium="Print"><Volume>374</Volume>
<Issue>1</Issue>
<PubDate><Year>2008</Year>
<Month>Apr</Month>
<Day>25</Day>
</PubDate>
</JournalIssue>
<Title>Virology</Title>
<ISOAbbreviation>Virology</ISOAbbreviation>
</Journal>
<ArticleTitle>The SARS-CoV ferret model in an infection-challenge study.</ArticleTitle>
<Pagination><MedlinePgn>151-63</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.virol.2007.12.032</ELocationID>
<Abstract><AbstractText>Phase I human clinical studies involving therapeutics for emerging and biodefense pathogens with low incidence, such as the severe acute respiratory syndrome coronavirus (SARS-CoV), requires at a minimum preclinical evaluation of efficacy in two well-characterized and robust animal models. Thus, a ferret SARS-CoV model was evaluated over a period of 58 days following extensive optimization and characterization of the model in order to validate clinical, histopathological, virological and immunological endpoints. Ferrets that were infected intranasally with 10(3) TCID50 SARS-CoV showed higher body temperature (2-6 d.p.i.), sneezing (5-10 d.p.i.), lesions (5-7 d.p.i.) and decreased WBC/lymphocytes (2-5 d.p.i.). SARS-CoV was detected up to 7 d.p.i. in various tissues and excreta, while neutralizing antibody titers rose at 7 d.p.i. and peaked at 14 d.p.i. At 29 d.p.i., one group was challenged with 10(3) TCID50 SARS-CoV, and an anamnestic response in neutralizing antibodies was evident with no detectable virus. This study supports the validity of the ferret model for use in evaluating efficacy of potential therapeutics to treat SARS.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chu</LastName>
<ForeName>Yong-Kyu</ForeName>
<Initials>YK</Initials>
<AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Southern Research Institute, Birmingham, AL, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ali</LastName>
<ForeName>Georgia D</ForeName>
<Initials>GD</Initials>
</Author>
<Author ValidYN="Y"><LastName>Jia</LastName>
<ForeName>Fuli</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>Qianjun</ForeName>
<Initials>Q</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kelvin</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Couch</LastName>
<ForeName>Ronald C</ForeName>
<Initials>RC</Initials>
</Author>
<Author ValidYN="Y"><LastName>Harrod</LastName>
<ForeName>Kevin S</ForeName>
<Initials>KS</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hutt</LastName>
<ForeName>Julie A</ForeName>
<Initials>JA</Initials>
</Author>
<Author ValidYN="Y"><LastName>Cameron</LastName>
<ForeName>Cheryl</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Weiss</LastName>
<ForeName>Susan R</ForeName>
<Initials>SR</Initials>
</Author>
<Author ValidYN="Y"><LastName>Jonsson</LastName>
<ForeName>Colleen B</ForeName>
<Initials>CB</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>N01 AI030063</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>N01AI30063</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D023361">Validation Study</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2008</Year>
<Month>01</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Virology</MedlineTA>
<NlmUniqueID>0110674</NlmUniqueID>
<ISSNLinking>0042-6822</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001831" MajorTopicYN="N">Body Temperature</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005289" MajorTopicYN="N">Ferrets</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007958" MajorTopicYN="N">Leukocyte Count</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018655" MajorTopicYN="N">Lymphocyte Count</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009296" MajorTopicYN="N">Nasal Cavity</DescriptorName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010614" MajorTopicYN="N">Pharynx</DescriptorName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year>
<Month>09</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2007</Year>
<Month>10</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2007</Year>
<Month>12</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2008</Year>
<Month>2</Month>
<Day>1</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2008</Year>
<Month>5</Month>
<Day>23</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2008</Year>
<Month>2</Month>
<Day>1</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">18234270</ArticleId>
<ArticleId IdType="pii">S0042-6822(07)00845-8</ArticleId>
<ArticleId IdType="doi">10.1016/j.virol.2007.12.032</ArticleId>
<ArticleId IdType="pmc">PMC2831213</ArticleId>
<ArticleId IdType="mid">NIHMS47612</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Lancet. 2003 Jul 26;362(9380):263-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12892955</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Med Virol. 2005 Feb;75(2):185-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15602737</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2003 Oct 10;302(5643):276-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12958366</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Am J Pathol. 2004 Jun;164(6):1893-900</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15161626</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2005 May 2;23(24):3202-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15837221</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Philos Trans R Soc Lond B Biol Sci. 2004 Jul 29;359(1447):1081-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15306393</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 May 17;361(9370):1701-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12767737</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Apr;78(7):3572-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15016880</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2005 May;79(9):5833-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15827197</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Infect Dis. 2004 Jul;10(7):1293-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15324552</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2004 Jun 26;363(9427):2139-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15220038</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>JAMA. 2003 Jun 4;289(21):2801-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12734147</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>ILAR J. 2006;47(4):348-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16963814</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Annu Rev Immunol. 2001;19:523-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11244046</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lab Anim Sci. 1992 Jun;42(3):222-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1320150</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2005 Dec;19(4):312-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16415986</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Infect Dis. 2003 Sep;9(9):1064-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14519241</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Pediatrics. 2004 Jan;113(1 Pt 1):e7-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14702488</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Infect Immun. 2004 Aug;72(8):4410-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15271897</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Pediatrics. 2003 Oct;112(4):e261</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14523209</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Trends Mol Med. 2003 Aug;9(8):325-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12928032</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS Med. 2006 May;3(5):e149</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16605302</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Infect Dis. 2006 Mar 1;193(5):685-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16453264</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vet Pathol. 1997 May;34(3):225-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9163879</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Curr Opin Biotechnol. 2003 Dec;14(6):641-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14662395</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Nov;78(22):12672-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15507655</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Rev Infect Dis. 1988 Jan-Feb;10(1):56-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3281223</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2005 Mar 18;23(17-18):2273-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15755610</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS Pathog. 2007 Jan;3(1):e5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17222058</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Pediatr Pulmonol Suppl. 2004;26:69-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15029602</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Arch Dis Child. 2004 Jun;89(6):551-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15155402</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Thorax. 2003 Aug;58(8):686-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12885985</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Infect Dis. 2003 Nov;9(11):1453-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14718090</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2003 Oct 30;425(6961):915</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14586458</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Pathol. 2005 Jul;206(3):251-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15892035</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 May 24;361(9371):1761-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12781533</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Pediatrics. 2004 Jun;113(6):e535-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15173534</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virus Res. 2004 Jul;103(1-2):91-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15163495</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2005 Jan;79(1):503-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15596843</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 Dec 18;349(25):2431-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14681510</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2004 Dec 5;330(1):8-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15527829</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1992 Feb;66(2):956-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1309922</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Curr Opin Infect Dis. 2006 Oct;19(5):429-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16940865</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS Med. 2006 May;3(5):e194</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16608385</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Clin Chem. 2003 Dec;49(12):2085-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14633884</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Paediatr Respir Rev. 2003 Dec;4(4):334-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14629957</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Clin Exp Immunol. 2004 Apr;136(1):95-103</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15030519</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Oct;78(20):11401-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15452262</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2005 Oct 28;310(5748):676-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16195424</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Pediatr Crit Care Med. 2003 Jul;4(3):279-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12831407</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Oct;78(20):11416-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15452265</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C24 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001C24 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:18234270
   |texte=   The SARS-CoV ferret model in an infection-challenge study.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:18234270" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

The SARS-CoV ferret model in an infection-challenge study.

The SARS-CoV ferret model in an infection-challenge study.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki